Search

Your search keyword '"Hillmen P."' showing total 1,312 results

Search Constraints

Start Over You searched for: Author "Hillmen P." Remove constraint Author: "Hillmen P."
1,312 results on '"Hillmen P."'

Search Results

202. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukemia

205. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry

206. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

207. The european hematology association roadmap for european hematology research: A consensus document

208. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

209. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS

210. LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP

211. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.

213. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial

214. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

215. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukemia

216. Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

218. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

219. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

220. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

221. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

222. Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)

223. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials

225. Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

226. Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials

227. Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

228. Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

229. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria

230. The European Hematology Association Roadmap for European Hematology Research: a consensus document.

231. The european hematology association roadmap for european hematology research: A consensus document

232. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

233. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

234. PATTERNS OF IDELALISIB TREATMENT-EMERGENT LYMPHOCYTOSIS IN PATIENTS WITH CLL OR SLL

235. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

237. The Management of Pregnancy in Paroxysmal Nocturnal Hemoglobinuria on Long Term Eculizumab

238. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

239. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

241. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

242. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases

243. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

244. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

245. Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results

246. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors

247. Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion

249. Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

250. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Catalog

Books, media, physical & digital resources